Larry Sutton, MD, PhD, discussed how oxygen affects C. difficile and provides anti-inflammatory effects in the gut, with potential applications for gastrointestinal diseases.
Larry Sutton, MD, PhD
Advertisement
CEO of Lopoxy Therapeutics and Clinical Scientist.
Articles by Larry Sutton, MD, PhD
CEO Larry Sutton, MD, PhD, discusses SIDIPREV, a novel oxygen-based therapy aimed at preventing C difficile infections.
Advertisement
Latest Updated Articles
Fighting C difficile Before It Starts: Lopoxy Therapeutics ApproachPublished: January 10th 2025 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Phase 3 Trial Confirms Superior Efficacy of Oral Pritelivir for Refractory HSV in Immunocompromised Patients
2
Developing the Next Generation of Rifamycins for Non-TB Mycobacteria in a Post-Antibiotic Era
3
Higher Acceptability of 1 Injectable in First Head-to-Head Comparison of Long-Acting PrEP
4
